These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21641231)

  • 1. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?
    Penel N; Adenis A; Bocci G
    Crit Rev Oncol Hematol; 2012 Apr; 82(1):40-50. PubMed ID: 21641231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
    Shaked Y; Emmenegger U; Francia G; Chen L; Lee CR; Man S; Paraghamian A; Ben-David Y; Kerbel RS
    Cancer Res; 2005 Aug; 65(16):7045-51. PubMed ID: 16103050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long clinical benefit achieved in two patients with malignant paraganglioma treated by metronomic cyclophosphamide.
    Gillon P; Godbert Y; Dupin C; Bubien V; Italiano A; Roubaud G
    Future Oncol; 2014 Nov; 10(14):2121-5. PubMed ID: 25471026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma.
    Bracha S; Walshaw R; Danton T; Holland S; Ruaux C; Obradovich J
    J Small Anim Pract; 2014 Jul; 55(7):369-74. PubMed ID: 24803081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.
    Gebbia V; Boussen H; Valerio MR
    Anticancer Res; 2012 Feb; 32(2):529-36. PubMed ID: 22287742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.
    Denies S; Cicchelero L; de Rooster H; Daminet S; Polis I; Van de Maele I; Sanders NN
    Vet Comp Oncol; 2017 Jun; 15(2):594-605. PubMed ID: 26961119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
    Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic oral cyclophosphamide in patients with advanced solid tumors.
    Bojko P; Schimmel G; Bosse D; Abenhardt W
    Onkologie; 2012; 35(1-2):35-8. PubMed ID: 22310343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
    Samaritani R; Corrado G; Vizza E; Sbiroli C
    BMC Cancer; 2007 Apr; 7():65. PubMed ID: 17433113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
    Lord R; Nair S; Schache A; Spicer J; Somaihah N; Khoo V; Pandha H
    J Urol; 2007 Jun; 177(6):2136-40; discussion 2140. PubMed ID: 17509300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature.
    Nelius T; Rinard K; Filleur S
    Cancer Treat Rev; 2011 Oct; 37(6):444-55. PubMed ID: 21277093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy.
    Gebbia V; Martorana F; Scandurra G; Valerio MR; Cufari S; Vigneri P; Sanò MV; Scollo P
    J Oncol Pharm Pract; 2024 Jul; 30(5):853-859. PubMed ID: 37501558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
    Nicolini A; Mancini P; Ferrari P; Anselmi L; Tartarelli G; Bonazzi V; Carpi A; Giardino R
    Biomed Pharmacother; 2004 Oct; 58(8):447-50. PubMed ID: 15464874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunomodulation and antiangiogenesis in cancer therapy. From basic to clinical research].
    Scharovsky OG; Matar P; Rozados VR; Rico MJ; Zacarías Fluck MF; Mainetti LE; Fernández Zenóbi MV; Roggero EA; Gervasoni SI; Rossa A; Perroud HA; Sánchez AM; Celoria GC; Font MT
    Medicina (B Aires); 2012; 72(1):47-57. PubMed ID: 22257459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
    Hermans IF; Chong TW; Palmowski MJ; Harris AL; Cerundolo V
    Cancer Res; 2003 Dec; 63(23):8408-13. PubMed ID: 14679003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of sterile hemorrhagic cystitis in tumor-bearing dogs concurrently treated with oral metronomic cyclophosphamide chemotherapy and furosemide: 55 cases (2009-2015).
    Chan CM; Frimberger AE; Moore AS
    J Am Vet Med Assoc; 2016 Dec; 249(12):1408-1414. PubMed ID: 27901449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12 electrogene therapy combined with metronomic cyclophosphamide in dogs with spontaneous cancer: A pilot study.
    Cicchelero L; Denies S; Vanderperren K; Stock E; Van Brantegem L; de Rooster H; Sanders NN
    Cancer Lett; 2017 Aug; 400():205-218. PubMed ID: 27693635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
    Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A
    J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.
    Young SD; Whissell M; Noble JC; Cano PO; Lopez PG; Germond CJ
    Clin Cancer Res; 2006 May; 12(10):3092-8. PubMed ID: 16707607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.